Sign in
Stories
Axsome Under Investigation for CMC Practices
Share
AMYLYX PHARMACEUTICALS Lawsuit Deadline ...
AVXL Lawsuit Roils Investors
AVXL Lawsuit: Deceptive Practices Expose...
Bluebird Bio Stock Lawsuit
COVID-19 Test Kits Lawsuit Alert
Investor Alert: Amylyx Pharmaceuticals L...
Overview
API
Bragar Eagel & Squire, P.C. is investigating potential claims against Axsome Therapeutics, Inc. for alleged deficient CMC practices. This follows a class action complaint citing overstatement of regulatory and commercial prospects, resulting in a major stock price drop post FDA response.
Ask a question
How could this incident impact investor confidence in the pharmaceutical industry as a whole?
How might the outcome of this investigation affect Axsome's long-term stockholders?
What measures can biotech companies like Axsome take to prevent regulatory overstatement?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage